Acceleron Pharma

Investors & Media

Press Releases

Date Title and Summary View
Toggle Summary Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Facioscapulohumeral Muscular Dystrophy
– ACE-083 did not achieve statistically significant improvements in functional endpoints relative to placebo – – Acceleron to discontinue development of ACE-083 in facioscapulohumeral muscular dystrophy – – Topline results from the Phase 2 trial of ACE-083 in Charcot-Marie-Tooth disease expected in
View HTML
Toggle Summary Acceleron Receives FDA Orphan Drug Designation for Sotatercept in Pulmonary Arterial Hypertension
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 9, 2019-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (
View HTML
Toggle Summary Acceleron Reports Second Quarter 2019 Operating and Financial Results
- BLA and MAA filings of luspatercept for beta-thalassemia- and myelodysplastic syndromes-associated anemia accepted by U.S. Food and Drug Administration and European Medicines Agency , respectively - - Acceleron receives $25 million milestone payment from Celgene for luspatercept’s BLA acceptance
View HTML
Toggle Summary Acceleron to Webcast Second Quarter 2019 Operating and Financial Results on August 5, 2019
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 24, 2019-- Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Monday, August 5, 2019 at 5:00 p.m. EDT to discuss its second quarter 2019 operating and financial results.
View HTML
Toggle Summary Acceleron Completes Target Enrollment in the PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension
- Company now expects to report top-line results in the first quarter of 2020 - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 26, 2019-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and
View HTML
Toggle Summary Acceleron Announces Retirement of Director and Co-Founder Tom Maniatis
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 10, 2019-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today that company co-founder Tom Maniatis , PhD, is
View HTML
Toggle Summary Celgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-Thalassemia
U.S. Food and Drug Administration grants priority review for beta-thalassemia indication and sets target action date of December 4, 2019 U.S. Food and Drug Administration sets target action date of April 4, 2020 for myelodysplastic syndromes indication Luspatercept EU Marketing Authorization
View HTML
Toggle Summary Acceleron to Present at the UBS Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 14, 2019-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that members of the management team will present at
View HTML
Toggle Summary Acceleron Reports First Quarter 2019 Operating and Financial Results
– Luspatercept Biologics License Application (BLA) and Marketing Authorization Application (MAA) submitted in April 2019 – – Part 2 results from the ACE-083 Phase 2 trials in facioscapulohumeral muscular dystrophy (FSHD) expected in the second half of 2019 and Charcot-Marie-Tooth disease (CMT)
View HTML
Toggle Summary Acceleron to Webcast First Quarter 2019 Operating and Financial Results on May 9, 2019
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 1, 2019-- Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, May 9, 2019 at 5:00 p.m. EDT to discuss its first quarter 2019 operating and financial results.
View HTML